SAS® Drug Development reinforces its market-leading position in life sciences

Bringing a new life sciences product to market requires the accurate, consistent and reliable analysis of substantial quantities of clinical trials data -- collected by a variety of different research partners in multiple locations.

For increasing numbers of research organizations, SAS has the answer to addressing this essential and daunting challenge.

SAS is the only company that offers an end-to-end solution to drive efficiencies throughout every stage of a drug's life cycle: from discovery through development, commercialization and beyond.

Why choose SAS?
Four years of research, development and customer feedback has secured SAS Drug Development firmly in place as the leading solution for the integration, analysis and reporting of research and clinical information. SAS Drug Development is the only solution that is fully integrated -- supporting industry data standards and easily working with an organization's existing technologies. SAS Drug Development leverages the strength of the SAS®9 Enterprise Intelligence Platform to enable the collation, analysis and reporting of clinical research information. It enables collaboration across geographies, trials, phases and therapeutic areas via a secure, centralized repository.

SAS continues to invest heavily in the life sciences, and no other vendor has more successful clinical analysis and reporting software implementations. In an industry where accurate, trustworthy data is crucial, SAS is widely recognized as the de-facto standard for clinical data analysis and FDA submissions.

Unlike other solutions that may have extensive implementation time frames, SAS Drug Development can be deployed, tested and validated within a very short implementation cycle with SAS hosting.

With a solid track record of satisfied customers and an extensive partner network, life sciences organizations can feel confident that SAS will provide stronger value -- and significant return on investment.

A growing global customer base
Building relationships with electronic data capture vendors and contract research organizations has contributed to the steady increase in SAS Drug Development customers. More than 25 life sciences organizations now use SAS Drug Development. In addition to a recent sale at INC Research®, SAS Drug Development customers include Daiichi Sankyo Pharma Development and Solvay Pharmaceuticals.

"Even as compliance pressures continue to mount and profits continue to tighten, life science companies remain eager for a system capable of the longitudinal analysis of clinical trial data," said Chris Connor, Senior Research Analyst at IDC Health Industry Insights. "A data integration and analysis solution that can, in a cost-effective manner, simultaneously integrate clinical, operational and financial data is critical to the ability to conduct adaptive trials, and enables life science companies to compete in a market growing ever more uncertain. The capabilities of SAS Drug Development, when combined with the flexibility of deploying at the customer premises or as a hosted solution, offer a compelling solution for life science companies."

Partnering to expand focus, provide more cost-effective solutions
Using its partner channel, SAS is expanding its traditional focus in clinical development and biostatistics to other areas, such as drug safety, and sales and marketing. Another benefit of the partner channel is that it provides a cost-effective way for smaller organizations - which may traditionally shy away from SAS because of budget constraints - to have access to the benefits of the SAS platform.

"The growing use of SAS illustrates the increasing recognition by industry organizations of SAS' platform for life sciences as a key asset," said Jason Burke, Director of U.S. Life Sciences Strategy and Solutions. "This gives SAS customers many options to derive greater insights into their research and business performance in cost effective ways, and confidence that their investment in SAS' intelligence platform is broadly supported within the industry."

The life sciences partner community includes Cognizant, DataFlux, IMS Health and JMP.

Customers validate that SAS' solution is the gold standard for analyzing clinical trial data.